Guidance and quality standards Awaiting development

Skip to filters Skip to results

Showing 51 to 75 of 345

Guidance and quality standards awaiting development
Title	Type
Cabozantinib with nivolumab and ipilimumab for untreated intermediate- or poor-risk advanced renal cell carcinoma [ID6330]	Technology appraisal guidance
CAEL-101 with standard care for untreated amyloid light chain amyloidosis TS ID 10666	Technology appraisal guidance
Canagliflozin for treating type 2 diabetes in people 10 to 17 years TS ID 11888	Technology appraisal guidance
Capivasertib with paclitaxel for untreated metastatic triple-negative breast cancer [ID6383]	Technology appraisal guidance
Caval valve implantation for tricuspid regurgitation	Interventional procedures guidance
Cenobamate for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy TS ID 10214	Technology appraisal guidance
Children and young people with disabilities and severe complex needs: integrated health and social care support	Quality standard
Concizumab for preventing bleeding episodes in haemophilia A or haemophilia B [ID5099]	Technology appraisal guidance
Corticosteroid-releasing bioabsorbable stent or spacer insertion during endoscopic sinus surgery to treat chronic rhinosinusitis	Interventional procedures guidance
Dabigatran etexilate for the secondary prevention of stroke after an embolic stroke of undetermined source (ID1417)	Technology appraisal guidance
Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma in people aged 12 to 17 TS ID 11839	Technology appraisal guidance
Dabrafenib, trametinib or both for treating BRAF V600 mutation-positive unresectable or metastatic melanoma in people aged 12 and over TS ID 11838	Technology appraisal guidance
Daratumumab for treating high-risk smouldering multiple myeloma [ID6214]	Technology appraisal guidance
Daratumumab in combination for untreated multiple myeloma when high-dose chemotherapy and autologous stem cell transplant are suitable ID6249	Technology appraisal guidance
Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer TS ID 12010	Technology appraisal guidance
Datopotamab deruxtecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy TS ID 11840	Technology appraisal guidance
Degarelix before or with radiotherapy for treating high-risk localised and locally advanced hormone-dependent prostate cancer TS ID 11933	Technology appraisal guidance
Delgocitinib for treating moderate to severe chronic hand eczema ID6408	Technology appraisal guidance
Dersimelagon for treating erythropoietic protoporphyria and X-linked protoporphyria in people 12 years and over TS ID 10392	Technology appraisal guidance
Deucravacitinib for treating active psoriatic arthritis TS ID 11981	Technology appraisal guidance
Dexamethasone intracanalicular insert for treating inflammation and pain after cataract surgery ID1154	Technology appraisal guidance
Digital front door for people accessing NHS Talking Therapies	Diagnostics guidance
Digital platforms for community based self-management of mild to moderate osteoarthritis and joint pain	Medical technologies guidance
Digital platforms to support cardiac rehabilitation	Medical technologies guidance
Diverticular disease	Quality standard

Results per page

10
25
50
All